Type 2 Diabetes Mellitus and Pancreatic Cancer

Surgical Clinics of North America

Volumn 93, Issue 3, 2013, Pages 619-627

  McAuliffe, John C ^a   Christein, John D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Pancreatectomy; Pancreatic cancer; Type 2 diabetes mellitus

Indexed keywords

GASTRIN; GHRELIN; GLUCAGON; GLUCOSE; INSULIN; SOMATOSTATIN;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; GASTROINTESTINAL SECRETION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE RELEASE; HUMAN; INSULIN RELEASE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PANCREAS; PANCREAS CANCER; PANCREAS FUNCTION; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET DELTA CELL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SMOKING; SURGICAL MORTALITY;

DIABETES MELLITUS, TYPE 2; HUMANS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 84876991747     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2013.02.003     Document Type: Review

References (50)

1. Sharma C., Eltawil K.M., Renfrew P.D., et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011, 17(7):867-897.
2. Vincent A., Herman J., Schulick R., et al. Pancreatic cancer. Lancet 2011, 378(9791):607-620.
3. Panel NP. Pancreatic adenocarcinoma. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology 2012.
4. American Diabetes Association Executive summary: Standards of medical care in diabetes-2012. Diabetes Care 2012, 35(Suppl 1):S4-S10.
5. Kleinman R.M., Gingerich R., Ohning G., et al. Intraislet regulation of pancreatic polypeptide secretion in the isolated perfused rat pancreas. Pancreas 1997, 15(4):384-391.
6. Brunicardi F.C., Druck P., Seymour N.E., et al. Splanchnic neural regulation of pancreatic polypeptide release in the isolated perfused human pancreas. Am J Surg 1989, 157(1):50-57.
7. Ebert R., Creutzfeldt W. Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 1987, 3(1):1-26.
8. Kleinman R., Gingerich R., Ohning G., et al. The influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas. Int J Pancreatol 1995, 18(1):51-57.
9. Yamada Y., Post S.R., Wang K., et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992, 89(1):251-255.
10. Gerich J.E., Campbell P.J., Kennedy F.P. Non-beta-cell islet abnormalities in noninsulin-dependent diabetes mellitus. Prog Clin Biol Res 1988, 265:133-150.
11. Cryer P.E. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012, 153(3):1039-1048.
12. Permert J., Ihse I., Jorfeldt L., et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993, 159(2):101-107.
13. Gullo L., Pezzilli R., Morselli-Labate A.M., et al. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994, 331(2):81-84.
14. Everhart J., Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995, 273(20):1605-1609.
15. Huxley R., Ansary-Moghaddam A., Berrington de González A., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92(11):2076-2083.
16. Chari S.T., Leibson C.L., Rabe K.G., et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005, 129(2):504-511.
17. Pannala R., Leirness J.B., Bamlet W.R., et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008, 134(4):981-987.
18. Chari S.T., Leibson C.L., Rabe K.G., et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008, 134(1):95-101.
19. Pannala R., Basu A., Petersen G.M., et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009, 10(1):88-95.
20. Schwarts S.S., Zeidler A., Moossa A.R., et al. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis 1978, 23(12):1107-1114.
21. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012, 51(1):64-74.
22. Chari S.T., Zapiach M., Yadav D., et al. Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 2005, 5(2-3):229-233.
23. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008, 114(1):63-70.
24. Powell D.R., Suwanichkul A., Cubbage M.L., et al. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 1991, 266(28):18868-18876.
25. Stoeltzing O., Liu W., Reinmuth N., et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003, 163(3):1001-1011.
26. Ohmura E., Okada M., Onoda N., et al. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 1990, 50(1):103-107.
27. Basso D., Millino C., Greco E., et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 2004, 53(8):1159-1166.
28. Magruder J.T., Elahi D., Andersen D.K. Diabetes and pancreatic cancer: chicken or egg?. Pancreas 2011, 40(3):339-351.
29. Pezzilli R., Casadei R., Morselli-Labate A.M. Is type 2 diabetes a risk factor for pancreatic cancer?. JOP 2009, 10(6):705-706.
30. Li D., Yeung S.C., Hassan M.M., et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137(2):482-488.
31. Varadarajulu S., Eloubeidi M.A. The role of endoscopic ultrasonography in the evaluation of pancreatico-biliary cancer. Surg Clin North Am 2010, 90(2):251-263.
32. Hutter M.M., Rowell K.S., Devaney L.A., et al. Identification of surgical complications and deaths: an assessment of the traditional surgical morbidity and mortality conference compared with the American College of Surgeons-National Surgical Quality Improvement Program. J Am Coll Surg 2006, 203(5):618-624.
33. Kelly K.J., Greenblatt D.Y., Wan Y., et al. Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. J Gastrointest Surg 2011, 15(2):250-259. [discussion: 259-61].
34. Parikh P., Shiloach M., Cohen M.E., et al. Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB (Oxford) 2010, 12(7):488-497.
35. Pitt H.A., Kilbane M., Strasberg S.M., et al. ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford) 2009, 11(5):405-413.
36. Pratt W., Joseph S., Callery M.P., et al. POSSUM accurately predicts morbidity for pancreatic resection. Surgery 2008, 143(1):8-19.
37. Charlson M.E., Sax F.L., MacKenzie C.R., et al. Resuscitation: how do we decide? A prospective study of physicians' preferences and the clinical course of hospitalized patients. JAMA 1986, 255(10):1316-1322.
38. Hill J.S., Zhou Z., Simons J.P., et al. A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Ann Surg Oncol 2010, 17(7):1802-1807.
39. Venkat R., Puhan M.A., Schulick R.D., et al. Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg 2011, 146(11):1277-1284.
40. Vollmer C.M., Sanchez N., Gondek S., et al. A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg 2012, 16(1):89-102. [discussion: 102-3].
41. Chagpar R.B., Martin R.C., Ahmad S.A., et al. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. J Gastrointest Surg 2011, 15(4):551-557.
42. Chu C.K., Mazo A.E., Sarmiento J.M., et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. J Am Coll Surg 2010, 210(4):463-473.
43. Chu C.K., Mazo A.E., Goodman M., et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010, 17(2):502-513.
44. Hartwig W., Hackert T., Hinz U., et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011, 254(2):311-319.
45. Cannon R.M., LeGrand R., Chagpar R.B., et al. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford) 2012, 14(4):228-235.
46. Pfeffer F., Nauck M.A., Benz S., et al. Secondary diabetes in pancreatic carcinoma and after pancreatectomy: pathophysiology, therapeutic peculiarities and prognosis. Z Gastroenterol 1999, (Suppl 1):10-14. [in German].
47. Hamilton L., Jeyarajah D.R. Hemoglobin A1c can be helpful in predicting progression to diabetes after Whipple procedure. HPB (Oxford) 2007, 9(1):26-28.
48. Permert J., Ihse I., Jorfeldt L., et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993, 80(8):1047-1050.
49. Litwin J., Dobrowolski S., Orłowska-Kunikowska E., et al. Changes in glucose metabolism after Kausch-Whipple pancreatectomy in pancreatic cancer and chronic pancreatitis patients. Pancreas 2008, 36(1):26-30.
50. White M.A., Agle S.C., Fuhr H.M., et al. Impact of pancreatic cancer and subsequent resection on glycemic control in diabetic and nondiabetic patients. Am Surg 2011, 77(8):1032-1037.